关键词: BRAF V600E突变, 甲状腺乳头状癌, 预后, 联合检测

Abstract: Thyroid cancer is the malignant tumor with the most rapidly increasing incidence in recent years. Papillary thyroid carcinoma accounts for approximately 90% of thyroid cancers. Though thyroid cancer is generally associated with favorable prognosis, there are still some patients appear local recurrence and distant metastasis. Molecular marker detections of BRAF V600E combined with TERT, miRNAs and P53 contributes to evaluate prognosis and risk of recurrence, helping identify PTC patients who are most likely to have poor prognosis.

Key words: BRAFV600E mutation, Papillary thyroid carcinoma, Prognosis, Combined detection